• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

24.21 +0.81 (+3.46%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ultragenyx Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 23, 2026
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
January 20, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
January 13, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
January 12, 2026
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 07, 2026
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
January 06, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
December 30, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
December 30, 2025
If approved, DTX401 will be the first therapy approved to treat the underlying cause of GSDIa 
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta
December 29, 2025
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 19, 2025
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx to Participate in Investor Conferences in December
November 24, 2025
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 21, 2025
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update
November 04, 2025
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences
November 04, 2025
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups
October 30, 2025
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update
October 28, 2025
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 24, 2025
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2025
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President
September 30, 2025
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 19, 2025
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
September 08, 2025
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
September 02, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
Ultragenyx to Participate at Investor Conferences in September
August 29, 2025
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
August 29, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
August 25, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 21, 2025
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
August 21, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)
August 18, 2025
Company expects to complete BLA submission in the fourth quarter of 2025 
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
August 17, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
August 13, 2025
From Pomerantz LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap